Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

MODIFy · Multi-Omic study of transcription factor Dose-Induced cell Fate

HORIZONStatus: SIGNED1 July 202630 June 2028EU funding €292,119Call HORIZON-MSCA-2025-PF

MODIFy (Multi-Omic study of transcription factor Dose-Induced cell Fate) is a multimodal experimental and computational project aimed at dissecting the interplay between human genetic variability and transcription factor (TF) dose in the context of human induced pluripotent stem cell (hiPSC) differentiation. Transcription factors (TFs) establish a cell’s gene expression profile, and their overexpression can induce cell state and even cell identity changes such as reprogramming of human somatic cells into hiPSCs. hiPSCs can then be differentiated into specific cell types for therapeutic purposes. However, hiPSC differentiation is highly heterogeneous and inefficient. This is due to molecular complexities including variability in the expression levels of the inducing TFs and differences in pluripotency among hiPSC lines, which can be driven by genetic variation. MODIFy aims to dissect the determinants of hiPSC differentiation heterogeneity by studying the interplay between TF expression level (dose) and genetic background at the single cell level. To this end, I will build on scTF-seq, a method developed in the Deplancke lab that enables systematic assessment of TF-induced cell state transitions across a wide dose range with single cell RNA sequencing (scRNA-seq). I will extend scTF-seq by incorporating a multimodal readout that combines transcriptomic and chromatin accessibility profiling, and apply it to genetically different hiPSC lines. This will allow me to decipher the gene regulatory networks activated at different TF doses and uncover how genetic variation influences them by modulating TF dose sensitivity. By combining my experience in in vitro differentiation, method development and bioinformatics with the expertise of Prof. Deplancke’s lab in scRNA-seq this project will yield fundamental insights into how TF dose and genotype interact to control cell fate,ultimately guiding improved strategies for cell engineering across diverse human genetic background.

Consortium · 1 organisation

coordinator

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

CH · €292,119

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.